Skip to main content
. 2016 Nov 25;107(12):1800–1805. doi: 10.1111/cas.13079

Figure 2.

Figure 2

Survival curves in patients with epidermal growth factor receptor (EGFR)‐mutated lung adenocarcinoma and brain metastases (BM), according to treatment with EGFR–tyrosine kinase inhibitor (TKI) alone or with whole‐brain radiotherapy (WBRT). (a) Intracranial time to progression (TTP). (b) Intracranial TTP in patients with symptomatic brain metastases. (c) Intracranial TTP in patients with asymptomatic brain metastases. (d) Overall survival.